

88. An immunogenic composition comprising an immunogenic hepatitis C virus (HCV) polypeptide in substantially isolated form wherein said immunogenic polypeptide comprises a region selected from the group consisting of an envelope domain of an HCV genome and immunogenic fragments of said envelope polypeptide.

89. A composition according to claim 88 wherein said polypeptide is from an E2 domain of an HCV genome.

90. A composition according to claim 88 wherein said polypeptide is from an E1 domain of an HCV genome.

91. A composition according to claim 88 wherein said polypeptide is an E1/E2 aggregate.

92. An immunogenic composition according to claim 88 further comprising an immunogenic HCV polypeptide wherein said immunogenic polypeptide comprises a region selected from the group consisting of a core domain of an HCV genome and immunogenic fragments of said core polypeptide.

93. An immunogenic composition comprising an immunogenic HCV polypeptide wherein said polypeptide comprises a region selected from the group consisting of a core domain of an HCV genome and immunogenic fragments of said core polypeptide.

94. An immunogenic composition comprising an immunogenic HCV polypeptide wherein said polypeptide comprises a region selected from the group consisting of a NS1 domain of an HCV genome and immunogenic fragments of said NS1 polypeptide.

95. An immunogenic composition comprising an immunogenic polypeptide wherein said polypeptide comprises a region selected from the group consisting of a NS2 domain of an HCV genome and immunogenic fragments of said NS2 polypeptide.

96. An immunogenic composition according to any one of claims 88 to 95 wherein said immunogenic HCV polypeptide or fragment comprises an amino acid sequence of at least 10 contiguous amino acids encoded by a genome of HCV.

97. The composition of claim 96 wherein said HCV polypeptide or fragment comprises an amino acid sequence of at least 15 contiguous amino acids encoded by a genome of HCV.

98. An immunogenic composition according to claim 96 wherein said HCV genome is HCV-1.

99. An immunogenic composition according to claim 97 wherein said HCV genome is HCV-1.

100. A composition according to any one of claims 88 to 95 wherein said HCV genome encodes a polyprotein comprising an amino acid sequence as shown in Figure 14.

101. A composition according to any one of claims 88 to 95 wherein said HCV genome encodes a polyprotein comprising an amino acid sequence as shown in Figure 47.

102. A composition according to any one of claims 88 to 95 wherein said HCV genome encodes a polyprotein comprising an amino acid sequence as shown in Figure 1.

103. A composition according to any one of claims 88 to 95 wherein said HCV genome encodes a polyprotein comprising an amino acid sequence as shown in Figure 3.

104. A composition according to any one of claims 88 to 95 wherein immunogenic polypeptide or fragments is encoded by a HCV nucleotide sequence of the lambda-gt11 cDNA library deposited under ATCC No. 40394, or ATCC No. 40388, or ATCC No. 40389, or ATCC No. 40390, or ATCC No. 40391, or ATCC No. 40514, or ATCC No. 40511, or ATCC NO. 40512, or ATCC No. 40513.

105. A composition according to any one of claims 88 to 95 wherein said HCV genome hybridizes.

106. A composition according to any one of claims 88 to 95 wherein said HCV genome is capable of selectively hybridizing a HCV polynucleotide or its complement under conditions which form stable duplexes between homologous regions.